<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006723</article-id><article-id pub-id-type="pmc">PMC11860193</article-id><article-id pub-id-type="doi">10.3390/vaccines13020176</article-id><article-id pub-id-type="publisher-id">vaccines-13-00176</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>COVID-19 Vaccination and Acute Anterior Uveitis&#x02014;A Case Control Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4366-5438</contrib-id><name><surname>Shemer</surname><given-names>Asaf</given-names></name><xref rid="af1-vaccines-13-00176" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00176" ref-type="aff">2</xref><xref rid="c1-vaccines-13-00176" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3395-0868</contrib-id><name><surname>Toledano</surname><given-names>Amit</given-names></name><xref rid="af1-vaccines-13-00176" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00176" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2678-1955</contrib-id><name><surname>Altarescu</surname><given-names>Aya</given-names></name><xref rid="af1-vaccines-13-00176" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00176" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Dubinsky-Pertzov</surname><given-names>Biana</given-names></name><xref rid="af1-vaccines-13-00176" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00176" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0339-5063</contrib-id><name><surname>Rozenberg</surname><given-names>Assaf</given-names></name><xref rid="af1-vaccines-13-00176" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00176" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Hecht</surname><given-names>Idan</given-names></name><xref rid="af1-vaccines-13-00176" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00176" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Einan-Lifshitz</surname><given-names>Adi</given-names></name><xref rid="af1-vaccines-13-00176" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00176" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Pras</surname><given-names>Eran</given-names></name><xref rid="af1-vaccines-13-00176" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00176" ref-type="aff">2</xref><xref rid="af3-vaccines-13-00176" ref-type="aff">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Maggi</surname><given-names>Fabrizio</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Bordi</surname><given-names>Licia</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00176"><label>1</label>Department of Ophthalmology, Shamir Medical Center (Formerly Assaf-Harofeh), Tzrifin 70300, Israel; <email>amitoled@gmail.com</email> (A.T.); <email>ganonaya@gmail.com</email> (A.A.); <email>bianad@gmail.com</email> (B.D.-P.); <email>assafroz@gmail.com</email> (A.R.); <email>idanhe@gmail.com</email> (I.H.); <email>adi.einan@gmail.com</email> (A.E.-L.); <email>eranpras@gmail.com</email> (E.P.)</aff><aff id="af2-vaccines-13-00176"><label>2</label>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel</aff><aff id="af3-vaccines-13-00176"><label>3</label>The Matlow&#x02019;s Ophthalmo-Genetics Laboratory, Department of Ophthalmology, Shamir Medical Center (Formerly Assaf-Harofeh), Tzrifin 70300, Israel</aff><author-notes><corresp id="c1-vaccines-13-00176"><label>*</label>Correspondence: <email>shemerasafmd@gmail.com</email>; Tel.: +972-8-9779620; Fax: +972-8-9779627</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>176</elocation-id><history><date date-type="received"><day>19</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>26</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>07</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Objective: To evaluate the association between the BNT162b2 (Pfizer-BioNTech<sup>&#x000ae;</sup>) coronavirus disease vaccine and new-onset anterior uveitis. Methods: A retrospective case control study of patients admitted and diagnosed with new-onset acute anterior uveitis, and matched controls admitted for other reasons (1:3 ratio), was completed. Rates of exposure to the BNT162b2 vaccine were compared between groups, and odds ratios for exposure to the vaccine were calculated. A secondary analysis of the overall number of patients with new-onset anterior uveitis in the six preceding years was conducted. This study was conducted in one academic center in Israel. Results: A total of 16 patients were admitted for acute anterior uveitis during the study period. Of the 16 cases, 11 (69%) received the first dose of the BNT162b2 vaccine prior to presentation and 8 (50%) also received the second dose. This compares to 39 (81.2%) in the control group. The odds ratio for exposure to the vaccine among cases was 0.508 (95% confidence interval 0.141&#x02013;1.829, <italic toggle="yes">p</italic> = 0.300). Compared with preceding years, the rate of cases diagnosed with acute anterior uveitis in 2021 was similar to the six preceding years (mean 11.8 &#x000b1; 3.4 cases). Conclusions: In this case control study and comparison with preceding years, we found no evidence to suggest an association between vaccination with the BNT162b2 (Pfizer-BioNTech<sup>&#x000ae;</sup>) COVID-19 vaccine and new-onset acute anterior uveitis.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>coronavirus</kwd><kwd>BNT162b2</kwd><kwd>vaccine</kwd><kwd>uveitis</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00176"><title>1. Introduction</title><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious virus that causes coronavirus-19 (COVID-19). Since its occurrence, millions of people have died of COVID-19 worldwide and many more have suffered from its complications [<xref rid="B1-vaccines-13-00176" ref-type="bibr">1</xref>]. COVID-19 infection has also been associated with the development of long-term autoimmune and inflammatory processes such as immune thrombocytopenic purpura, Guillain&#x02013;Barre syndrome, Bells&#x02019; palsy, antiphospholipid syndrome, and more [<xref rid="B2-vaccines-13-00176" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-13-00176" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-13-00176" ref-type="bibr">4</xref>].</p><p>As of December 2020, several COVID-19 vaccines were approved with emergency authorization by the US Food and Drug Administration with high efficacy rates and good safety profiles [<xref rid="B5-vaccines-13-00176" ref-type="bibr">5</xref>]. Yet, the initial clinical trial included only about 40,000 participants. In light of the high morbidity and mortality, Israel and other countries worldwide initiated a massive vaccination campaign for the general population. Initially, Israeli adult citizens were vaccinated with the BNT162b2 (Pfizer-BioNTech) vaccine only. This m-RNA vaccine was given twice 21 days apart and the majority of Israel&#x02019;s population (&#x0003e;4,000,000 m) was vaccinated. Due to the resurgence of COVID-19, the Israeli Ministry of Health campaigned for a third and fourth dose of the vaccination to the general adult population gradually [<xref rid="B6-vaccines-13-00176" ref-type="bibr">6</xref>].</p><p>Uveitis refers to a group of diseases characterized by intraocular inflammation. Uveitis affects all age groups and can lead to harmful visual impairment. As it is occasionally associated with systemic disorders, early diagnosis and treatment are warranted [<xref rid="B7-vaccines-13-00176" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-13-00176" ref-type="bibr">8</xref>]. Vaccine-associated uveitis has been previously described in cases such as immunization for the hepatitis B virus (HBV), human papillomavirus (HPV), influenza virus, Bacille Calmette&#x02013;Guerin (BCG), measles&#x02013;mumps&#x02013;rubella (MMR), and more. Although the mechanism is not fully elucidated, either the adjuvant&#x02019;s secondary inflammation or antigenic mimicry are implicated [<xref rid="B9-vaccines-13-00176" ref-type="bibr">9</xref>].</p><p>Over the past few years, several studies have examined the immune response following BNT162b2 vaccination, including large cohort studies, with inconsistent results [<xref rid="B10-vaccines-13-00176" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-13-00176" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-13-00176" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-13-00176" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-13-00176" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-13-00176" ref-type="bibr">15</xref>]. In this study, we aim to evaluate the association of new-onset anterior uveitis in patients recently vaccinated with the BNT162b2 (Pfizer-BioNTech) vaccine.</p></sec><sec sec-type="methods" id="sec2-vaccines-13-00176"><title>2. Methods</title><p>This study adhered to the tenets of the Declaration of Helsinki and was approved by the institutional review board (IRB) of the Shamir Medical Center. Given the retrospective nature of the study, a waiver of informed consent was granted by the IRB, as the research involved the use of anonymized patient data collected from medical records without direct patient involvement. This study was conducted in one academic referral center: Shamir Medical Center (formerly &#x0201c;Assaf Harofeh&#x0201d;). This is the fourth-largest governmental medical center in Israel. The center serves a diverse patient population, providing a robust setting for clinical research.</p><p>In this case control study, we investigated the association between exposure to the BNT162b2 vaccine (at least one dose) and acute anterior uveitis. All patients that were admitted to the emergency department (ED) of our academic medical center and were diagnosed with a first episode of anterior uveitis were classified as cases. Cases were collected from 1 January 2021 to 30 September 2021 via a hospital computerized system according to ICD-9 code (364.00&#x02014;acute and subacute iridocyclitis, unspecified). We retrospectively reviewed each medical chart and manually recorded rates and timings of vaccination with the BNT162b2 vaccine. Patients older than 18 years were included, while patients with a previous uveitis episode were excluded. For controls, we blinded randomly matched patients admitted to our ED for any reason other than acute uveitis. Age, sex, and admission date within 48 h were matched in a 1:3 ratio between the groups. In both groups, the percentage of patients exposed to the BNT162b2 vaccine (first or second dose) at any time and within the previous 30 days was calculated and the odds ratio for exposure were compared with corresponding confidence intervals.</p><p>As a secondary analysis, all patients diagnosed with acute anterior uveitis during the same time period (January&#x02013;September) in the six preceding years, before the introduction of the COVID-19 disease or vaccine, were extracted and the data were compared to the cases, which represents the number of patients with anterior uveitis in the same time period.</p><sec id="sec2dot1-vaccines-13-00176"><title>2.1. COVID-19 Vaccination Timeline</title><p>The US Food and Drug Administration (FDA) issued an emergency use authorization for the BNT162b2 (Pfizer-BioNTech<sup>&#x000ae;</sup>, Mainz, Germany) vaccine, received in December 2020. It was authorized for all individuals older than 16 years and was injected in two doses separated by a 21-day interval. Later, in August 2021, a full license was given for the BNT162b2 vaccine [<xref rid="B13-vaccines-13-00176" ref-type="bibr">13</xref>]. The Israeli national vaccination campaign began on 19 December 2020, and by 1 September 2021, approximately 85% of the adult population over the age of 20 were already vaccinated [<xref rid="B6-vaccines-13-00176" ref-type="bibr">6</xref>].</p></sec><sec id="sec2dot2-vaccines-13-00176"><title>2.2. Statistical Analysis</title><p>Statistical analysis was performed using IBM SPSS Statistics 25 (IBM Corp. Armonk, NY, USA). Unless otherwise specified, data are presented as mean &#x000b1; standard deviation (SD). Categorical variables were compared using the chi-square test. Clinical parameter distributions were tested for normality by the Shapiro&#x02013;Wilk test. Independent T-tests were conducted for continuous variables with a normal distribution and the Mann&#x02013;Whitney U test was used for variables with a non-normal distribution. The odds ratio (OR) for exposure to the vaccine was calculated with the corresponding 95% confidence interval. Absolute Risk Reduction (ARR) was calculated to quantify the change in risk of acute anterior uveitis associated with vaccination. ARR was determined by subtracting the risk in the study group from the risk in the control group. The Number Needed to Treat (NNT) was calculated as the reciprocal of the ARR. <italic toggle="yes">p</italic>-values less than 0.05 on a two-sided test were considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00176"><title>3. Results</title><p>During the study period, a total of 16 patients were diagnosed with acute anterior uveitis in the ED. The mean patient age was 41.4 &#x000b1; 19.6 years (range: 18&#x02013;75 years) and 56.3% were female. The left eye was involved in six cases, the right in nine cases, and a bilateral disease was seen in one case.</p><p>On presentation, all patients had an anterior chamber reaction and, per our exclusion criteria, no vitreal, retinal, or choroidal involvement was seen. The disease was idiopathic in 14 cases, suspected to be associated with Beh&#x000e7;et&#x02019;s disease in 1 case, and was HLA-B27-associated in another. In one case, elevated intraocular pressure (IOP) was seen (31 mmHg), while, in the other cases, IOP was normal (&#x0003c;21 mmHg). Of the sixteen patients, three (18.7%) had diabetes mellitus, four (25%) had hypertension, one (6.2%) had a personal history of immune- or inflammatory-associated disorders (ankylosing spondylitis), and two (12.5%) had a family history of immune- or inflammatory-associated disorders (Beh&#x000e7;et&#x02019;s disease). None had a previous episode. A detailed description of the patients is provided in <xref rid="vaccines-13-00176-t001" ref-type="table">Table 1</xref>. Of the 16 cases, 11 (69%) received the first dose of the BNT162b2 vaccine prior to presentation (mean time after vaccine: 177 &#x000b1; 85 days, range: 15&#x02013;311 days) and 8 (50%) also received the second dose prior to presentation (mean time after vaccine: 166 &#x000b1; 57 days, range: 85&#x02013;230 days). Comparing fully vaccinated (50%, 8/16) to non-fully vaccinated patients (50%, 8/16) showed no statistically significant differences in age (48.0 &#x000b1; 20.6 years vs. 34.8 &#x000b1; 17.3, <italic toggle="yes">p</italic> = 0.190) or gender (50% males vs. 37.5%, <italic toggle="yes">p</italic> = 0.614).</p><p>For each patient admitted for an episode of acute anterior uveitis, three controls were randomly selected which were matched for age, sex, and date of admission. Among the controls, common reasons for admission were chest pain, abdominal pain, and syncope. Overall, 11 patients (68%) with acute anterior uveitis were previously vaccinated with the first dose of the BNT162b2 vaccine compared to 39 (81.2%) in the control group (<xref rid="vaccines-13-00176-t002" ref-type="table">Table 2</xref>). The unadjusted odds ratio (OR) for exposure to the vaccine among cases was 0.508 (95% confidence interval [95%CI] was 0.141&#x02013;1.829, <italic toggle="yes">p</italic> = 0.300). When comparing fully vaccinated individuals (first and second dose), 8 patients (50%) with acute anterior uveitis were previously vaccinated compared to 75% (36/48) in the control group. In this case, the unadjusted OR for exposure to the vaccine among cases was 0.333 (95%CI was 0.103&#x02013;1.082, <italic toggle="yes">p</italic> = 0.068). The Absolute Risk Reduction (ARR) for vaccination was calculated as 25% (ARR = 0.75&#x02013;0.50). The Number Needed to Treat (NNT), defined as the number of individuals who need to be vaccinated to prevent a case of acute anterior uveitis, was 4 (NNT = 1/ARR).</p><p>Focusing on recently vaccinated patients (&#x02264;30 days), one case (6.2%, 1/16) with acute anterior uveitis was recently vaccinated with the first dose compared to four cases (8.3%) in the control group (OR: 0.733 95%CI: 0.076&#x02013;7.08, <italic toggle="yes">p</italic> = 0.789). Furthermore, when comparing fully vaccinated individuals (first and second dose), no patient (0%) with acute anterior uveitis was recently vaccinated (&#x02264;30 days) compared to four patients (8.3%) in the control group (<italic toggle="yes">p</italic> = 0.233).</p><p>As a secondary analysis, a comparison of the overall number of patients with acute anterior uveitis was made to preceding years before the emergence of COVID-19 and the introduction of the BNT162b2 vaccine. <xref rid="vaccines-13-00176-t003" ref-type="table">Table 3</xref> shows the number of cases in the six preceding years. Admission rates for acute anterior uveitis were similar in the preceding years compared to 2021 with a mean of 11.8 &#x000b1; 3.4 cases (range: 8&#x02013;17; <xref rid="vaccines-13-00176-t003" ref-type="table">Table 3</xref>).</p></sec><sec sec-type="discussion" id="sec4-vaccines-13-00176"><title>4. Discussion</title><p>Uveitis may be associated with various systemic diseases. These diseases can be infectious and non-infectious. Of the non-infectious uveitis, systemic autoimmune or auto-inflammatory disease may be involved [<xref rid="B12-vaccines-13-00176" ref-type="bibr">12</xref>]. Among the autoimmune diseases, uveitis was found to be connected to sarcoidosis, HLA-B27 disease, Multiple Sclerosis, and more [<xref rid="B14-vaccines-13-00176" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-13-00176" ref-type="bibr">15</xref>]. Multi Inflammatory Syndrome (MIS-C) associated with COVID-19 infection in children and young adults can present with a varied clinical spectrum. Ocular findings can include bilateral conjunctivitis (as part of Kawasaki-like disease). There are also reports of uveitis being the ocular-presenting symptom in COVID-19 patients [<xref rid="B16-vaccines-13-00176" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-13-00176" ref-type="bibr">17</xref>].</p><p>COVID-19 vaccines have also been reported to be connected to autoimmune diseases, such as myocarditis, vasculitis, and Guillain&#x02013;Barr&#x000e9; syndrome, and even endothelial keratoplasty rejection. In addition, many ocular adverse effects have been reported so far, including cranial nerve palsies, acute macular neuroretinopathy, central serous chorioretinopathy, Vogt&#x02013;Koyanagi&#x02013;Harada reactivation, multiple evanescent white dot syndrome, Graves&#x02019; disease, and more. Yet, the vast majority of studies are retrospective case reports and case series, which cannot imply causality [<xref rid="B18-vaccines-13-00176" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-13-00176" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-13-00176" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-13-00176" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-13-00176" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-13-00176" ref-type="bibr">23</xref>].</p><p>A retrospective population-based study, including over two million individuals who received the COVID-19 vaccine (with a matched cohort), reported a crude incidence rate of 47.1 per 100,000 person-years of non-infectious uveitis among vaccinated individuals compared to 50.6 per 100,000 in a historical non-vaccinated cohort. The adjusted hazard ratio was 0.91 (95% CI, 0.75&#x02013;1.10, <italic toggle="yes">p</italic> = 0.33). The authors concluded that the study did not identify an increased risk of non-infectious uveitis following COVID-19 vaccination in individuals without a prior history of uveitis, providing reassurance regarding the vaccine&#x02019;s overall safety [<xref rid="B24-vaccines-13-00176" ref-type="bibr">24</xref>]. Another retrospective population-based study that assessed the association between BNT162b2 vaccine and the risk of non-infectious uveitis was published. Overall, 188 cases were reported after the first or second dose of the vaccine. The authors reported an age- and sex-related standardized incidence ratio (SIR) of 1.41 with a 21-day attributable risk of 1.12 cases per 100,000 patients that were vaccinated and an SIR of 1.31 with an attributable risk of 0.85 per 100,000 patients following the first and second COVID-19 vaccine, respectively. The authors concluded that, although the BNT162b2 vaccine may be associated with non-infectious uveitis, their results do not provide proof for a cause&#x02013;effect relationship [<xref rid="B25-vaccines-13-00176" ref-type="bibr">25</xref>].</p><p>In addition, one multicenter retrospective study was conducted to assess uveitis cases following the BNT162b2 mRNA vaccine. The authors found that cases of post-COVID-19-vaccine uveitis were mostly anterior and mild to moderate in severity with a mean time of 7.5 &#x000b1; 7.3 days between vaccinations to uveitis onset. Two patients developed multiple evanescent white dot syndrome (MEWDS) and one patient had a complicated anterior uveitis, which eventually involved mild vitreal haze and macular edema. Approximately 40% of patients had experienced a previous uveitic episode, and in only two cases, both eyes were involved. All patients completed a two-dose vaccination with the BNT162b2 COVID-19 vaccine. Most patients achieved complete resolution (or significant improvement) at the final follow-up. The authors suggested a possible link between the vaccine and uveitis via type-I interferon secretion that induced autoimmune reactivity in prone subjects. Finally, the authors concluded that, although uncommon, there is a possible association between BNT162b2 vaccine and uveitis [<xref rid="B26-vaccines-13-00176" ref-type="bibr">26</xref>].</p><p>Furthermore, there are a few case reports exploring the connection between uveitis and the COVID-19 vaccine. In one case, a 23-year-old male developed anterior uveitis 14 days after the second dose of the BNT162b2 vaccine. Ocular inflammatory signs resolved following topical steroidal treatment [<xref rid="B27-vaccines-13-00176" ref-type="bibr">27</xref>]. In another case, a juvenile idiopathic arthritis (JIA)-associated anterior uveitis was documented in an 18-year-old female five days following the second dose of the BBIBP-CorV inactivated vaccine (Sinopharm<sup>&#x000ae;</sup>). The patient was treated topically with prednisolone acetate 1% with full resolution. The authors of these reports implied that this phenomenon may be a response to vaccine adjuvants [<xref rid="B28-vaccines-13-00176" ref-type="bibr">28</xref>]. Additional case reports of a 50-year-old woman diagnosed with bilateral uveitis five days following immunization with the inactivated COVID-19 vaccine and a 27-year-old male with juvenile idiopathic arthritis and positive HLA B-27 were described. The patients experienced a flare-up following the ChAdOx1 (COVISHIELD<sup>&#x000ae;</sup>) COVID-19 vaccination. In both cases, the patients fully recovered after topical steroidal treatment. The authors suggested an upregulation of the innate immune system as a potential mechanism [<xref rid="B29-vaccines-13-00176" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-13-00176" ref-type="bibr">30</xref>]. However, given the mass vaccination in the population, it is likely that only some cases of uveitis will occur soon after vaccination completely by chance.</p><p>In this study, we looked at cases of anterior uveitis in na&#x000ef;ve patients in one academic center. A matched case control design was used in addition to a secondary historical case series analysis. Our findings are in accordance with the result presented by Rabinovitch et al. and by Tomkins-Netzer et al. in terms of patient characteristics, laterality, and resolution following topical treatment [<xref rid="B24-vaccines-13-00176" ref-type="bibr">24</xref>,<xref rid="B26-vaccines-13-00176" ref-type="bibr">26</xref>].</p><p>Our study has limitations. First, our study includes a small sample size, which limits the statistical power of our findings. While the occurrence of uveitis in vaccinated individuals may seem significant, the relatively small cohort size means that our results should be interpreted with caution. Second, a passive surveillance system of vaccine-related adverse effects may not identify all cases. Furthermore, our study methodology included only patients who received the ICD-9 code upon discharge. Such a classification may underestimate the true number of the cases. Third, the data presented herein are from a large medical center. Some straightforward anterior uveitis cases may have been treated by the community care system and were not referred for hospital care. Fourth, we excluded all cases of recurrent uveitis and, therefore, we cannot comment regarding a potential flare-up following COVID-19 immunizations. Finally, in this initial report, we could only address patients&#x02019; initial episode and outcome; yet, we cannot assess long-term effects or disease course over time. It is important to emphasize that this study does not aim to establish a causal relationship between the COVID-19 vaccine and the occurrence of uveitis. Given the observational nature of the case control design, we can only suggest a potential association, and causality cannot be inferred from our findings. Further studies with larger sample sizes and more robust methodologies are needed to explore any possible causal link. In discussing the association between COVID-19 vaccination and uveitis, it is important to acknowledge that COVID-19 vaccines have been shown to be protective against acute COVID-19 symptoms [<xref rid="B5-vaccines-13-00176" ref-type="bibr">5</xref>] as well as some persistent symptoms [<xref rid="B31-vaccines-13-00176" ref-type="bibr">31</xref>]. Our study does not aim to question or diminish the protective benefits of vaccination, which remain well established. We emphasize that our findings should not be misinterpreted as supporting any anti-vaccine agenda.</p><p>In conclusion, this study could not identify an association between the BNT162b2 vaccine and a new acute onset of anterior uveitis. Further multicenter prospective investigations are warranted to create a better understanding of the BNT162b2 vaccine effects. In our opinion, vaccine-related adverse events should be monitored and reported in order to allow the patient and the physician a better understanding of a newly authorized vaccine. However, in times of an acute global lethal pandemic, effective immunization is currently the most important action the public should carry out.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.S., B.D.-P., I.H., E.P., A.T. and A.A.; Data curation, A.S., A.T., A.A. and A.E.-L.; formal analysis, I.H. and B.D.-P.; methodology, A.S., I.H., E.P., A.E.-L. and A.R.; project administration, A.S. and E.P.; supervision, A.S., A.R., A.E.-L. and E.P.; writing&#x02014;original draft, A.S., A.T., A.A., B.D.-P. and I.H.; writing&#x02014;review &#x00026; editing, A.R., A.E.-L. and E.P.; final approval of the manuscript, A.S., A.T., A.A., B.D.-P., I.H., A.E.-L., A.R. and E.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Shamir Medical Center (Approval Code: ASF-0213-21; Approval Date: 25/10/2021).</p></notes><notes><title>Informed Consent Statement</title><p>Patient consent was waived due to the retrospective nature of the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data supporting the findings of this study are not publicly available due to privacy and ethical considerations.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00176"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>M.</given-names></name>
<name><surname>Adil</surname><given-names>S.F.</given-names></name>
<name><surname>Alkhathlan</surname><given-names>H.Z.</given-names></name>
<name><surname>Tahir</surname><given-names>M.N.</given-names></name>
<name><surname>Saif</surname><given-names>S.</given-names></name>
<name><surname>Khan</surname><given-names>M.</given-names></name>
<name><surname>Khan</surname><given-names>S.T.</given-names></name>
</person-group><article-title>COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far</article-title><source>Molecules</source><year>2020</year><volume>26</volume><elocation-id>39</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26010039</pub-id><pub-id pub-id-type="pmid">33374759</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00176"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ehrenfeld</surname><given-names>M.</given-names></name>
<name><surname>Tincani</surname><given-names>A.</given-names></name>
<name><surname>Andreoli</surname><given-names>L.</given-names></name>
<name><surname>Cattalini</surname><given-names>M.</given-names></name>
<name><surname>Greenbaum</surname><given-names>A.</given-names></name>
<name><surname>Kanduc</surname><given-names>D.</given-names></name>
<name><surname>Alijotas-Reig</surname><given-names>J.</given-names></name>
<name><surname>Zinserling</surname><given-names>V.</given-names></name>
<name><surname>Semenova</surname><given-names>N.</given-names></name>
<name><surname>Amital</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 and autoimmunity</article-title><source>Autoimmun. Rev.</source><year>2020</year><volume>19</volume><fpage>102597</fpage><pub-id pub-id-type="doi">10.1016/j.autrev.2020.102597</pub-id><pub-id pub-id-type="pmid">32535093</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00176"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yazdanpanah</surname><given-names>N.</given-names></name>
<name><surname>Rezaei</surname><given-names>N.</given-names></name>
</person-group><article-title>Autoimmune complications of COVID-19</article-title><source>J. Med. Virol.</source><year>2021</year><volume>94</volume><fpage>54</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1002/jmv.27292</pub-id><pub-id pub-id-type="pmid">34427929</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00176"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shemer</surname><given-names>A.</given-names></name>
<name><surname>Pras</surname><given-names>E.</given-names></name>
<name><surname>Hecht</surname><given-names>I.</given-names></name>
</person-group><article-title>Peripheral Facial Nerve Palsy following BNT162b2 (COVID-19) Vaccination</article-title><source>Isr. Med. Assoc. J.</source><year>2021</year><volume>23</volume><fpage>143</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">33734623</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00176"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Polack</surname><given-names>F.P.</given-names></name>
<name><surname>Thomas</surname><given-names>S.J.</given-names></name>
<name><surname>Kitchin</surname><given-names>N.</given-names></name>
<name><surname>Absalon</surname><given-names>J.</given-names></name>
<name><surname>Gurtman</surname><given-names>A.</given-names></name>
<name><surname>Lockhart</surname><given-names>S.</given-names></name>
<name><surname>Perez</surname><given-names>J.L.</given-names></name>
<name><surname>P&#x000e9;rez Marc</surname><given-names>G.</given-names></name>
<name><surname>Moreira</surname><given-names>E.D.</given-names></name>
<name><surname>Zerbini</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id>
</element-citation></ref><ref id="B6-vaccines-13-00176"><label>6.</label><element-citation publication-type="gov"><article-title>Datadashboard&#x02014;COVID-19 Israel Ministry of Heath</article-title><comment>Available online: <ext-link xlink:href="https://datadashboard.health.gov.il/COVID-19/general" ext-link-type="uri">https://datadashboard.health.gov.il/COVID-19/general</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-10-30">(accessed on 30 October 2021)</date-in-citation></element-citation></ref><ref id="B7-vaccines-13-00176"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>S&#x000e8;ve</surname><given-names>P.</given-names></name>
<name><surname>Cacoub</surname><given-names>P.</given-names></name>
<name><surname>Bodaghi</surname><given-names>B.</given-names></name>
<name><surname>Trad</surname><given-names>S.</given-names></name>
<name><surname>Sellam</surname><given-names>J.</given-names></name>
<name><surname>Bellocq</surname><given-names>D.</given-names></name>
<name><surname>Bielefeld</surname><given-names>P.</given-names></name>
<name><surname>S&#x000e8;ne</surname><given-names>D.</given-names></name>
<name><surname>Kaplanski</surname><given-names>G.</given-names></name>
<name><surname>Monnet</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Uveitis: Diagnostic work-up. A literature review and recommendations from an expert committee</article-title><source>Autoimmun. Rev.</source><year>2017</year><volume>16</volume><fpage>1254</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2017.10.010</pub-id><pub-id pub-id-type="pmid">29037906</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00176"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burkholder</surname><given-names>B.M.</given-names></name>
<name><surname>Jabs</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Uveitis for the non-ophthalmologist</article-title><source>BMJ</source><year>2021</year><volume>372</volume><elocation-id>m4979</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.m4979</pub-id><pub-id pub-id-type="pmid">33536186</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00176"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cunningham</surname><given-names>E.T.</given-names></name>
<name><surname>Moorthy</surname><given-names>R.S.</given-names></name>
<name><surname>Fraunfelder</surname><given-names>F.W.</given-names></name>
<name><surname>Zierhut</surname><given-names>M.</given-names></name>
</person-group><article-title>Vaccine-Associated Uveitis</article-title><source>Ocul. Immunol. Inflamm.</source><year>2019</year><volume>27</volume><fpage>517</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1080/09273948.2019.1626188</pub-id><pub-id pub-id-type="pmid">31247152</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00176"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jacobson</surname><given-names>D.L.</given-names></name>
<name><surname>Gange</surname><given-names>S.J.</given-names></name>
<name><surname>Rose</surname><given-names>N.R.</given-names></name>
<name><surname>Graham</surname><given-names>N.M.H.</given-names></name>
</person-group><article-title>Epidemiology and Estimated Population Burden of Selected Autoimmune Diseases in the United States</article-title><source>Clin. Immunol. Immunopathol.</source><year>1997</year><volume>84</volume><fpage>223</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1006/clin.1997.4412</pub-id><pub-id pub-id-type="pmid">9281381</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00176"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hidaka</surname><given-names>D.</given-names></name>
<name><surname>Ogasawara</surname><given-names>R.</given-names></name>
<name><surname>Sugimura</surname><given-names>S.</given-names></name>
<name><surname>Fujii</surname><given-names>F.</given-names></name>
<name><surname>Kojima</surname><given-names>K.</given-names></name>
<name><surname>Nagai</surname><given-names>J.</given-names></name>
<name><surname>Ebata</surname><given-names>K.</given-names></name>
<name><surname>Okada</surname><given-names>K.</given-names></name>
<name><surname>Kobayashi</surname><given-names>N.</given-names></name>
<name><surname>Ogasawara</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>New-onset Evans syndrome associated with systemic lupus erythematosus after BNT162b2 mRNA COVID-19 vaccination</article-title><source>Int. J. Hematol.</source><year>2021</year><volume>115</volume><fpage>424</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1007/s12185-021-03243-2</pub-id><pub-id pub-id-type="pmid">34687421</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00176"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shemer</surname><given-names>A.</given-names></name>
<name><surname>Pras</surname><given-names>E.</given-names></name>
<name><surname>Einan-Lifshitz</surname><given-names>A.</given-names></name>
<name><surname>Dubinsky-Pertzov</surname><given-names>B.</given-names></name>
<name><surname>Hecht</surname><given-names>I.</given-names></name>
</person-group><article-title>Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study</article-title><source>JAMA Otolaryngol. Head. Neck Surg.</source><year>2021</year><volume>147</volume><fpage>739</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1001/jamaoto.2021.1259</pub-id><pub-id pub-id-type="pmid">34165512</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00176"><label>13.</label><element-citation publication-type="gov"><article-title>Pfizer-BioNTech COVID-19 Vaccine|FDA</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine" ext-link-type="uri">https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-30">(accessed on 30 January 2021)</date-in-citation></element-citation></ref><ref id="B14-vaccines-13-00176"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>ten Berge</surname><given-names>J.C.</given-names></name>
<name><surname>Schreurs</surname><given-names>M.W.J.</given-names></name>
<name><surname>van Daele</surname><given-names>P.L.A.</given-names></name>
<name><surname>Rothova</surname><given-names>A.</given-names></name>
</person-group><article-title>Autoimmunity in uveitis</article-title><source>Acta Ophthalmol.</source><year>2018</year><volume>96</volume><fpage>481</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1111/aos.13652</pub-id><pub-id pub-id-type="pmid">29369534</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00176"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bertrand</surname><given-names>P.J.</given-names></name>
<name><surname>Jamilloux</surname><given-names>Y.</given-names></name>
<name><surname>Ecochard</surname><given-names>R.</given-names></name>
<name><surname>Richard-Colmant</surname><given-names>G.</given-names></name>
<name><surname>Gerfaud-Valentin</surname><given-names>M.</given-names></name>
<name><surname>Guillaud</surname><given-names>M.</given-names></name>
<name><surname>Denis</surname><given-names>P.</given-names></name>
<name><surname>Kodjikian</surname><given-names>L.</given-names></name>
<name><surname>S&#x000e8;ve</surname><given-names>P.</given-names></name>
</person-group><article-title>Uveitis: Autoimmunity&#x02026; and beyond</article-title><source>Autoimmun. Rev.</source><year>2019</year><volume>18</volume><fpage>102351</fpage><pub-id pub-id-type="doi">10.1016/j.autrev.2019.102351</pub-id><pub-id pub-id-type="pmid">31323361</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00176"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karthika</surname><given-names>I.K.</given-names></name>
<name><surname>Gulla</surname><given-names>K.M.</given-names></name>
<name><surname>John</surname><given-names>J.</given-names></name>
<name><surname>Satapathy</surname><given-names>A.K.</given-names></name>
<name><surname>Sahu</surname><given-names>S.</given-names></name>
<name><surname>Behera</surname><given-names>B.</given-names></name>
<name><surname>Mishra</surname><given-names>P.</given-names></name>
</person-group><article-title>COVID-19 related multi-inflammatory syndrome presenting with uveitis-A case report</article-title><source>Indian J. Ophthalmol.</source><year>2021</year><volume>69</volume><fpage>1319</fpage><lpage>1321</lpage><pub-id pub-id-type="pmid">33913889</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00176"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shemer</surname><given-names>A.</given-names></name>
<name><surname>Einan-Lifshitz</surname><given-names>A.</given-names></name>
<name><surname>Itah</surname><given-names>A.</given-names></name>
<name><surname>Dubinsky-Pertzov</surname><given-names>B.</given-names></name>
<name><surname>Pras</surname><given-names>E.</given-names></name>
<name><surname>Hecht</surname><given-names>I.</given-names></name>
</person-group><article-title>Ocular involvement in coronavirus disease 2019 (COVID-19): A clinical and molecular analysis</article-title><source>Int. Ophthalmol.</source><year>2020</year><volume>41</volume><fpage>433</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1007/s10792-020-01592-1</pub-id><pub-id pub-id-type="pmid">32929665</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00176"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trimboli</surname><given-names>M.</given-names></name>
<name><surname>Zoleo</surname><given-names>P.</given-names></name>
<name><surname>Arabia</surname><given-names>G.</given-names></name>
<name><surname>Gambardella</surname><given-names>A.</given-names></name>
</person-group><article-title>Guillain-Barr&#x000e9; syndrome following BNT162b2 COVID-19 vaccine</article-title><source>Neurol. Sci.</source><year>2021</year><volume>42</volume><fpage>4401</fpage><lpage>4402</lpage><pub-id pub-id-type="doi">10.1007/s10072-021-05523-5</pub-id><pub-id pub-id-type="pmid">34346014</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00176"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gaignard</surname><given-names>M.E.</given-names></name>
<name><surname>Lieberherr</surname><given-names>S.</given-names></name>
<name><surname>Schoenenberger</surname><given-names>A.</given-names></name>
<name><surname>Benz</surname><given-names>R.</given-names></name>
</person-group><article-title>Autoimmune Hematologic Disorders in Two Patients after mRNA COVID-19 Vaccine</article-title><source>HemaSphere</source><year>2021</year><volume>5</volume><elocation-id>e618</elocation-id><pub-id pub-id-type="doi">10.1097/HS9.0000000000000618</pub-id><pub-id pub-id-type="pmid">34263143</pub-id>
</element-citation></ref><ref id="B20-vaccines-13-00176"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dash</surname><given-names>S.</given-names></name>
<name><surname>Behera</surname><given-names>B.</given-names></name>
<name><surname>Sethy</surname><given-names>M.</given-names></name>
<name><surname>Mishra</surname><given-names>J.</given-names></name>
<name><surname>Garg</surname><given-names>S.</given-names></name>
</person-group><article-title>COVID-19 vaccine-induced urticarial vasculitis</article-title><source>Dermatol. Ther.</source><year>2021</year><volume>34</volume><elocation-id>e15093</elocation-id><pub-id pub-id-type="doi">10.1111/dth.15093</pub-id><pub-id pub-id-type="pmid">34369046</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00176"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salah</surname><given-names>H.M.</given-names></name>
<name><surname>Mehta</surname><given-names>J.L.</given-names></name>
</person-group><article-title>COVID-19 Vaccine and Myocarditis</article-title><source>Am. J. Cardiol.</source><year>2021</year><volume>157</volume><fpage>146</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2021.07.009</pub-id><pub-id pub-id-type="pmid">34399967</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00176"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Phylactou</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>J.P.O.</given-names></name>
<name><surname>Larkin</surname><given-names>D.F.P.</given-names></name>
</person-group><article-title>Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine</article-title><source>Br. J. Ophthalmol.</source><year>2021</year><volume>105</volume><fpage>893</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1136/bjophthalmol-2021-319338</pub-id><pub-id pub-id-type="pmid">33910885</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00176"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le Ng</surname><given-names>X.</given-names></name>
<name><surname>Betzler</surname><given-names>B.K.</given-names></name>
<name><surname>Testi</surname><given-names>I.</given-names></name>
<name><surname>Ho</surname><given-names>S.L.</given-names></name>
<name><surname>Tien</surname><given-names>M.</given-names></name>
<name><surname>Ngo</surname><given-names>W.K.</given-names></name>
<name><surname>Zierhut</surname><given-names>M.</given-names></name>
<name><surname>Chee</surname><given-names>S.P.</given-names></name>
<name><surname>Gupta</surname><given-names>V.</given-names></name>
<name><surname>Pavesio</surname><given-names>E.C.</given-names></name>
<etal/>
</person-group><article-title>Ocular Adverse Events After COVID-19 Vaccination</article-title><source>Ocul. Immunol. Inflamm.</source><year>2021</year><volume>29</volume><fpage>1216</fpage><lpage>1224</lpage><pub-id pub-id-type="pmid">34559576</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00176"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomkins-Netzer</surname><given-names>O.</given-names></name>
<name><surname>Sar</surname><given-names>S.</given-names></name>
<name><surname>Barnett-Griness</surname><given-names>O.</given-names></name>
<name><surname>Friedman</surname><given-names>B.</given-names></name>
<name><surname>Shyriaieva</surname><given-names>H.</given-names></name>
<name><surname>Saliba</surname><given-names>W.</given-names></name>
</person-group><article-title>Association between Vaccination with the BNT162b2 mRNA Coronavirus Disease 2019 Vaccine and Noninfectious Uveitis: A Population-Based Study</article-title><source>Ophthalmology</source><year>2022</year><volume>129</volume><fpage>1087</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2022.05.015</pub-id><pub-id pub-id-type="pmid">35643168</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00176"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Miller</surname><given-names>D.C.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Arnold</surname><given-names>B.F.</given-names></name>
<name><surname>Acharya</surname><given-names>N.R.</given-names></name>
</person-group><article-title>Risk of noninfectious uveitis after coronavirus disease 2019 vaccination in a United States claims database</article-title><source>Ophthalmology</source><year>2023</year><volume>130</volume><fpage>1269</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2023.07.017</pub-id><pub-id pub-id-type="pmid">37480943</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00176"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rabinovitch</surname><given-names>T.</given-names></name>
<name><surname>Ben-Arie-Weintrob</surname><given-names>Y.</given-names></name>
<name><surname>Hareuveni-Blum</surname><given-names>T.</given-names></name>
<name><surname>Shaer</surname><given-names>B.</given-names></name>
<name><surname>Vishnevskia-Dai</surname><given-names>V.</given-names></name>
<name><surname>Shulman</surname><given-names>S.</given-names></name>
<name><surname>Newman</surname><given-names>H.</given-names></name>
<name><surname>Biadsy</surname><given-names>M.</given-names></name>
<name><surname>Masarwa</surname><given-names>D.</given-names></name>
<name><surname>Fischer</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection</article-title><source>Retina</source><year>2021</year><volume>41</volume><fpage>2462</fpage><lpage>2471</lpage><pub-id pub-id-type="doi">10.1097/IAE.0000000000003277</pub-id><pub-id pub-id-type="pmid">34369440</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00176"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Renisi</surname><given-names>G.</given-names></name>
<name><surname>Lombardi</surname><given-names>A.</given-names></name>
<name><surname>Stanzione</surname><given-names>M.</given-names></name>
<name><surname>Invernizzi</surname><given-names>A.</given-names></name>
<name><surname>Bandera</surname><given-names>A.</given-names></name>
<name><surname>Gori</surname><given-names>A.</given-names></name>
</person-group><article-title>Anterior uveitis onset after bnt162b2 vaccination: Is this just a coincidence?</article-title><source>Int. J. Infect. Dis.</source><year>2021</year><volume>110</volume><fpage>95</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2021.07.035</pub-id><pub-id pub-id-type="pmid">34289406</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00176"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>ElSheikh</surname><given-names>R.H.</given-names></name>
<name><surname>Haseeb</surname><given-names>A.</given-names></name>
<name><surname>Eleiwa</surname><given-names>T.K.</given-names></name>
<name><surname>Elhusseiny</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Acute Uveitis following COVID-19 Vaccination</article-title><source>Ocul. Immunol. Inflamm.</source><year>2021</year><volume>29</volume><fpage>1207</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1080/09273948.2021.1962917</pub-id><pub-id pub-id-type="pmid">34379565</pub-id>
</element-citation></ref><ref id="B29-vaccines-13-00176"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pan</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Cui</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
</person-group><article-title>Bilateral uveitis after inoculation with COVID-19 vaccine: A case report</article-title><source>Int. J. Infect. Dis.</source><year>2021</year><volume>113</volume><fpage>116</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2021.09.075</pub-id><pub-id pub-id-type="pmid">34601147</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00176"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jain</surname><given-names>A.</given-names></name>
<name><surname>Kalamkar</surname><given-names>C.</given-names></name>
</person-group><article-title>COVID-19 vaccine-associated reactivation of uveitis</article-title><source>Indian J. Ophthalmol.</source><year>2021</year><volume>69</volume><fpage>2899</fpage><pub-id pub-id-type="doi">10.4103/ijo.IJO_1435_21</pub-id></element-citation></ref><ref id="B31-vaccines-13-00176"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Aly</surname><given-names>Z.</given-names></name>
<name><surname>Bowe</surname><given-names>B.</given-names></name>
<name><surname>Xie</surname><given-names>Y.</given-names></name>
</person-group><article-title>Long COVID after breakthrough SARS-CoV-2 infection</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1461</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01840-0</pub-id><pub-id pub-id-type="pmid">35614233</pub-id>
</element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="vaccines-13-00176-t001"><object-id pub-id-type="pii">vaccines-13-00176-t001_Table 1</object-id><label>Table 1</label><caption><p>Characteristics of patients with new-onset anterior uveitis after recent vaccination with the BNT162b2 (Pfizer-BioNTech) vaccine.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patient</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gender</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Comorbidities</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Laterality</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AC Cells *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AC Flare *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IOP *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Etiology</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Follow-Ups</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Status at<break/>Last Follow-Up</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Topical Steroids (Drops per Day)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Topical Mydriasis</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Topical Cycloplegia</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Recovery Time<break/>(Days)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Partially recovered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cataract</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully recovered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cataract, DMT2, HTN, IHD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Partially recovered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S/P perimyocarditis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ankylosing spondilitis, HTN, S/P bariatric surgery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ankylosing<break/>spondilitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully recovered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atopic dermatitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Partially recovered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Family history of Beh&#x000e7;et&#x02019;s disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">m/p Beh&#x000e7;et&#x02019;s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully recovered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully recovered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cataract, DMT2, HTN, Parkinson&#x02019;s disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully recovered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Axenfeld-Riger syndrome, psoriasis, f/h Beh&#x000e7;et&#x02019;s disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beh&#x000e7;et&#x02019;s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully recovered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully recovered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully recovered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully recovered</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cataract, HTN, dyslipidemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr></tbody></table><table-wrap-foot><fn><p>* At initial presentation. Abbreviations: AC, anterior chamber; DMT2, diabetes mellitus type 2; F, female; F/h, family history; HTN, hypertension; IHD, ischemic heart disease; L, left; M, male; M/p, most probably; N/A, not available; R, right; S/P, status post.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00176-t002"><object-id pub-id-type="pii">vaccines-13-00176-t002_Table 2</object-id><label>Table 2</label><caption><p>Distribution of vaccinated and non-vaccinated patients among cases with new-onset anterior uveitis and matched controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patient Group</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No. of Cases</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No. of Controls</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total No.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-vaccinated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-13-00176-t003"><object-id pub-id-type="pii">vaccines-13-00176-t003_Table 3</object-id><label>Table 3</label><caption><p>Cases with acute anterior uveitis admitted in 2021 and during the same period in the six preceding years.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cases</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age (Years)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Male Gender</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.2 &#x000b1; 16.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (53%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.1 &#x000b1; 17.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (62%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47.9 &#x000b1; 20.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (36%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.7 &#x000b1; 16.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (59%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.9 &#x000b1; 15.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (50%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.4 &#x000b1; 20.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (70%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.4 &#x000b1; 19.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (44%)</td></tr></tbody></table></table-wrap></floats-group></article>